Research Article

Increased Risk of Suicide among Cancer Survivors Who Developed a Second Malignant Neoplasm

Huazhen Yang,1,2 Yuanyuan Qu,1,2 Yanan Shang,1,2 Chengshi Wang,3,4 Junren Wang,1,2 Donghao Lu,1,5,6 and Huan Song1,2,7

1West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
2Med-X Center for Informatics, Sichuan University, Chengdu, China
3Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
4Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, China
5Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
6Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
7Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Correspondence should be addressed to Donghao Lu; donghao.lu@ki.se and Huan Song; songhuan@wchscu.cn

Received 4 November 2021; Accepted 7 December 2021; Published 10 January 2022

Academic Editor: Guangming Zhang

Copyright © 2022 Huazhen Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Cancer diagnosis entails substantial psychological distress and is associated with dramatically increased risks of suicidal behaviors. However, little is known about the suicide risk among cancer survivors who developed a second malignant neoplasm (SMN). Methods. Using the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study involving 7,824,709 patients with first malignant neoplasm (FMN). We measured the hazard ratios (HRs) of suicide death after receiving a SMN diagnosis using Cox proportional hazard models, as compared with patients with FMN. The comparison with the US population was achieved by calculating standardized mortality ratios (SMRs). Results. Totally 685,727 FMN patients received a diagnosis of SMN during follow-up, and we in total identified 10,930 and 937 suicide deaths among FMN and SMN patients, respectively. The HR of suicide deaths was 1.23 (95% confidence interval (CI), 1.14–1.31) after a SMN diagnosis, compared with FMN patients, after adjusting for sociodemographic factors, tumor characteristics, and cancer treatment. As compared with the general population, while both SMN and FMN patients suffered an increased risk of suicide deaths, the excess risk was higher among SMN patients than FMN patients (age-, sex-, and calendar-year-adjusted SMR 1.65 (95% CI 1.54–1.75) vs. 1.29 (95% CI 1.26–1.31); P_difference < 0.0001). Notably, across different time periods, we observed the greatest risk elevation during the first 3 months after a cancer diagnosis. Conclusions. Compared with either patients with FMN or the general population, cancer survivors who received a SMN diagnosis were at increased risk of suicide death. The risk elevation was most prominent soon after the cancer diagnosis, highlighting the necessity of providing timely psychological support to cancer survivors with a SMN.

1. Introduction

A growing number of patients are surviving from cancer because of the increased survival as well as the advances in cancer screening programs and novel treatments [1–3]. However, all cancer survivors are at risk for developing a second primary cancer [4–6]. It was reported that the incidence of second malignant neoplasm (SMN), calculated from the Surveillance, Epidemiology, and End Results (SEER) Program, was approximately 8.1% between 1992 and 2008 in the United States, indicating that nearly 1 in 12 cancer patients can develop a SMN [6].

Cancer is a devastating illness that comes with tremendous psychological distress [7–9]. Accumulating evidence has
shown that people diagnosed with cancer are at an elevated risk of suicidal behaviors, including complete suicide [10–12] and suicide attempts [13, 14], compared with the general population. Therefore, it is plausible that receiving a diagnosis of SMN, acting as a repeat and possibly stronger stressor, might further increase the risk of suicide among cancer survivors. Indeed, patients with subsequent primary cancers (i.e., two or more primary cancers) have been reported to be at elevated risk for poorer physical and mental health status (e.g., serious psychological distress) [15–18]. However, the risk of suicide among patients with SMN is unclear. Therefore, leveraging the population-based cancer cohort from the SEER database, which has stringent criteria for identifying multiple primary neoplasms, together with the aggregated US population data and US mortality data, we aimed to examine the risk of suicide among cancer survivors who developed a SMN.

2. Materials and Methods

2.1. Study Population. The SEER Program has collected cancer incidence and survival data from population-based cancer registries since 1973, covering approximately 34% of the US population as of 2016 [19]. Information on patient demographics, year and month of diagnosis, tumor characteristics (including primary tumor site, cancer behavior, tumor size, and tumor grade), treatment utilization, and active follow-up for vital status were routinely documented [20].

In the present study, we conducted a population-based cohort study using the SEER registry records between January 1, 1975, and December 31, 2016, in the United States. Among the 9,157,072 cancer patients (Figure 1), we excluded 114,866 who were diagnosed only through autopsy or death certificate, 1,409 with no information on birth year, 1,184,919 that recorded as not their first malignancy (670,225 with no information on primary malignancy and 514,694 with no information on FMN), and 31,169 with their deaths occurring before the SMN diagnosis to the unexposed group and to the exposed group from the time of diagnosis onward. All patients were followed from the diagnosis of FMN until death, the occurrence of a subsequent malignancy, or December 31, 2016, whichever occurred first. Because the SEER data provided only survival in months for survival analysis, we assigned an average survival time of 15 days for individuals who died in the same month of diagnosis.

By linking to the subsequent malignancy diagnoses in SEER, we identified 685,727 patients who developed a SMN during the follow-up who therefore were included in the exposed group. Namely, patients without a SMN diagnosis contributed all person-time to the unexposed group, while the ones with a SMN diagnosis contributed their person-time before the SMN diagnosis to the unexposed group and to the exposed group from the time of diagnosis onward.

2.2. Ascertainment of FMN and SMN. We first identified patients with a FMN diagnosis according to the SEER collected tumor information on the primary tumor (yes or no), tumor behavior (malignant or not), and first malignant primary indicator (yes or no). Through linkage to the information on subsequent cancer diagnoses, we then further identified individuals with a SMN diagnosis among these FMN survivors. In a subanalysis, we performed separate analyses on prostate cancer, breast cancer, colorectal cancer, lung cancer, nonmelanoma skin cancer, cancer of the central nervous system, severe cancer (esophageal, liver, or pancreatic cancer), and other cancers, as well as lifestyle-related cancers (alcohol- and smoking-related cancers) [21], according to the International Classification of Disease Oncology (ICD-O) third edition codes (Supplementary Table 1).

2.3. Ascertainment of Suicide. Based on the cause-specific death classification both for SEER and US mortality data, which was derived from the death certificate, we considered individuals to have committed suicide if the cause of death was coded as suicide and self-inflicted injury, with the corresponding International Classification of Diseases (ICD) 10th edition (ICD-10) codes as U03, X60-X84, and Y87.0.

2.4. Covariates. Data on potential confounders, including birth year, sex, calendar year at diagnosis, sociodemographic factors (i.e., race, cohabitation status, insurance, and state), tumor characteristic (i.e., tumor size and grade), and cancer treatment (i.e., chemotherapy, radiotherapy, and surgery), were obtained from the SEER database. All missing values of the covariates were coded to the “unknown” category. The corresponding information on age at death, sex, and calendar year for the US population data were derived from the US Census Bureau’s Population Estimates Program.

2.5. Statistical Analysis. We assessed the relative risk of suicide in relation to SMN diagnosis compared with FMN patients, using hazard ratios (HRs) with 95% confidence intervals (CI) derived from Cox regression models. Models were partly (models 1–3) or fully (model 4) adjusted for the birth year (as a continuous variable), sex (male or female), calendar year at diagnosis (1975–1984, 1985–1994, 1995–2004, or 2005–2016), race (white, black, or others/unknown), cohabitation status (cohabitation, noncohabitation, or unknown), insurance (insured, uninsured, or unknown), state (Alaska, California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, Louisiana, Michigan, New Jersey, New Mexico, Utah, or Washington), tumor size (<1.5, ≥1.5 cm, or unknown), tumor grade (well, moderately, poorly differentiated/undifferentiated, or unknown), chemotherapy/radiotherapy (yes or no/unknown), and surgery (yes or no/unknown). We also examined the association between SMN diagnosis and subsequent risk of suicide death by cancer subtypes, after controlling for available confounders. Lifestyle factors (i.e., alcohol drinking and smoking) might modify the studied association. We therefore also separately analyzed alcohol-related cancers and smoking-related cancers.
In subgroup analyses, HRs were calculated separately by age at diagnosis (by quantile: <55, 55–65, 66–75, or >75 years), calendar year at diagnosis, sex, race, cohabitation status, tumor size, tumor grade, chemotherapy/radiotherapy, surgery, and the time interval between FMN and SMN. Furthermore, we explored whether the relative risk of suicide after a SMN diagnosis varied across different time periods since cancer diagnosis, by analyzing the associations in different follow-up periods (<1, 1–2, 3–4, 5–10, or >10 years). Additionally, we calculated the HRs by characteristics of their first malignancies (i.e., tumor characteristics and treatment utilization) to explore the potential modified role of first malignancy among SMN patients. The statistical significance of the difference between HRs was assessed by including an interaction term in the Cox model.

To better interpret our findings, we also calculated standardized mortality ratios (SMRs; i.e., the ratio of the observed to the expected number of suicide deaths) with 95% CIs to estimate the relative risk for suicide after SMN, as well as FMN, using the general US population as reference. Specifically, the number of expected suicide deaths was calculated by multiplying the observed number of person-years by age-(5 year strata), sex-, and calendar-year-specific suicide rates derived from the general US population. We further estimated SMRs by different follow-up periods (i.e., <1, 1–2, 3–4, 5–10, or >10 years) after the SMN or FMN diagnosis to examine the immediate and long-term impact. The statistical significance of the difference between SMRs was assessed by the heterogeneity test.

To test the robustness of the observed associations, we repeated the main analysis excluding SMN patients with a prior history of FMN at the same tumor site. We further assessed the potential influence of unmeasured confounders using the E-value [22]. All the analyses were conducted in R software (version 4.0). A two-sided P-value <0.05 was considered statistically significant.

### Results

Of the 9,157,072 cancer patients in the SEER data, we identified 7,824,709 FMN patients in the population-based cohort, among which 685,727 individuals were exposed to a SMN diagnosis during up to 42 years of the follow-up period (Figure 1). With a total of 46,507,112 accumulated person-years, the median follow-up time was 1.67 (Q1–Q3: 0.42–5.00) and 3.17 (0.67–8.67) years for the SMN and FMN patients, respectively (Table 1). There was little difference in race, cohabitation status, state, and tumor grade between the SMN and FMN patients. However, compared with the FMN patients, patients with a SMN diagnosis were more likely to be male (58.97% vs. 51.28%), older (mean age 71.00 vs. 63.60 years), insured (49.46% vs. 38.82%), with larger tumor size (46.92% vs. 42.31%), and not treated (37.35% vs. 44.32% and 53.46% vs. 58.59% for chemotherapy/radiotherapy and surgery, respectively).

During follow-up, a total of 937 suicide deaths (crude incidence rate, 3.90 per 10,000 person-years) and 10,930 suicide deaths (2.48 per 10,000 person-years) were identified among SMN patients and FMN patients, respectively (Table 2). Correspondingly, we observed a consistently elevated relative risk of suicide among SMN patients compared with FMN patients across different models; the fully adjusted HR (model 4) was 1.23 (95% CI 1.14–1.31). Similar risk elevations were observed for alcohol-related cancers (HR 1.37; 95% CI 1.10–1.72; Figure 2) and smoking-related cancers (HR 1.18; 95% CI 1.06–1.31). Furthermore, among all studied cancer subtypes defined by the sites of SMN, the HRs were most pronounced when SMN was severe cancer (HR 1.97; 95% CI 1.48–2.63) or lung cancer (HR 1.57; 95% CI 1.34–1.86; Figure 2).

In a subanalysis, the excess risk of suicide in SMN patients did not differ by calendar year, sex, race, cohabitation status, tumor grade, tumor size, chemotherapy/
Table 1: Characteristics of the study cohort.

| Characteristic                      | SMN²(N = 685727) | FMN²(N = 7824709) |
|-------------------------------------|------------------|-------------------|
| Follow-up time, mean (SD), y        | 3.50 (4.47)      | 5.64 (6.53)       |
| Follow-up time, median (Q1–Q3), y   | 1.67 (0.42–5.00) | 3.17 (0.67–8.67)  |
| Birth year, mean (SD), y            | 1,930 (14.70)    | 1,940 (18.50)     |
| Age at diagnosis, mean (SD), y      | 71.00 (11.60)    | 63.60 (15.10)     |

| Age group (by quantile), no. (%), y | SMN² | FMN²   |
|------------------------------------|------|--------|
| <55                                | 58,180 (8.48) | 1,939,983 (24.79) |
| 55–66                              | 159,108 (23.20) | 2,300,439 (29.40) |
| 67–75                              | 206,746 (30.15) | 1,827,392 (23.35) |
| >75                                | 261,693 (38.16) | 1,756,895 (22.45) |

| Calendar year, no. (%)            | SMN² | FMN²   |
|------------------------------------|------|--------|
| 1975–1984                          | 26,808 (3.91) | 668,993 (8.55) |
| 1985–1994                          | 74,360 (10.84) | 988,075 (12.63) |
| 1995–2004                          | 163,161 (23.79) | 2,194,895 (28.05) |
| 2005–2016                          | 421,398 (61.45) | 3,972,746 (50.77) |

| Sex, no. (%)                       | SMN² | FMN²   |
|------------------------------------|------|--------|
| Male                               | 404,391 (58.97) | 4,012,867 (51.28) |
| Female                             | 281,336 (41.03) | 3,811,842 (48.72) |

| Race, no. (%)                      | SMN² | FMN²   |
|------------------------------------|------|--------|
| White                              | 586,494 (85.53) | 6,427,454 (82.14) |
| Black                              | 63,114 (9.20) | 797,649 (10.19) |
| Others/unknown                     | 36,119 (5.27) | 599,606 (7.66) |

| Cohabitation status, no. (%)       | SMN² | FMN²   |
|------------------------------------|------|--------|
| Cohabitation                       | 249,999 (36.46) | 2,940,863 (37.58) |
| Noncohabitation                    | 390,221 (56.91) | 4,351,566 (55.61) |
| Unknown                            | 45,507 (6.64) | 532,280 (6.80) |

| Insurance, no. (%)                 | SMN² | FMN²   |
|------------------------------------|------|--------|
| Insured                            | 339,146 (49.46) | 3,037,767 (38.82) |
| Uninsured                          | 3,822 (0.56) | 90,885 (1.16) |
| Unknown                            | 342,759 (49.98) | 4,696,057 (60.02) |

| State, no. (%)                     | SMN² | FMN²   |
|------------------------------------|------|--------|
| Alaska                             | 533 (0.08) | 7,495 (0.10) |
| California                         | 216,848 (31.62) | 2,767,483 (35.37) |
| Connecticut                        | 63,227 (9.22) | 603,280 (7.71) |
| Georgia                            | 56,227 (8.20) | 733,285 (9.37) |
| Hawaii                             | 15,738 (2.30) | 169,385 (2.16) |
| Iowa                               | 55,057 (8.03) | 508,535 (6.50) |
| Kentucky                           | 26,320 (3.84) | 337,028 (4.31) |
| Louisiana                          | 23,977 (3.50) | 320,179 (4.09) |
| Michigan                           | 73,514 (10.72) | 676,773 (8.63) |
| New Jersey                         | 52,786 (7.70) | 664,090 (8.49) |
| New Mexico                         | 17,921 (2.61) | 223,539 (2.86) |
| Utah                               | 19,001 (2.77) | 220,849 (2.82) |
| Washington                         | 64,578 (9.42) | 592,788 (7.58) |

| Cancer sites, no. (%)              | SMN² | FMN²   |
|------------------------------------|------|--------|
| Prostate cancer                    | 70,992 (10.35) | 1,186,195 (15.16) |
| Breast cancer                      | 45,939 (6.70) | 1,188,792 (15.19) |
| Colorectal cancer                  | 82,991 (12.10) | 835,070 (10.67) |
| Lung cancer                        | 121,001 (17.65) | 975,192 (12.46) |
| Skin (nonmelanoma)                 | 4,064 (0.59) | 28,036 (0.36) |
| CNS¹ cancer                        | 6,630 (0.97) | 113,471 (1.45) |
| Severe cancer¹                     | 40,647 (5.93) | 388,774 (4.97) |
| Other cancers                      | 258,521 (37.70) | 2,526,393 (32.29) |

| Smoking-related cancers            | SMN² | FMN²   |
|------------------------------------|------|--------|
| No                                 | 434,306 (63.34) | 5,814,303 (74.31) |
| Yes                                | 251,421 (36.66) | 2,010,406 (25.69) |

| Alcohol-related cancers            | SMN² | FMN²   |
|------------------------------------|------|--------|
| No                                 | 648,254 (94.54) | 7,467,584 (95.44) |
| Yes                                | 37,473 (5.46) | 357,125 (4.56) |

¹ CNS: Central Nervous System
² SMN²: Study Mammography Network
³ FMN²: Follow-up Mammography Network
⁴ No: None smoking
⁵ Yes: smoked smoking
⁶ Race includes Other/unknown
Table 2: Risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by different adjustment strategies, compared with individuals with a first malignant neoplasm (FMN) diagnosis.

| Model information                           | SMN \(N=685727\) | FMN \(N=7824709\) | Hazard ratio (95% confidence interval) |
|---------------------------------------------|--------------------|--------------------|----------------------------------------|
| Different adjustment strategies\(a\)       |                    |                    |                                        |
| Model 1: adjusted for birth year, sex, and calendar year | 66,741 (9.73)     | 791,353 (10.11)    |                                        |
| Model 2: model 1 + sociodemographic factors (i.e., race, cohabitation status, insurance, and state) | 321,740 (46.92) | 3,310,859 (42.31) |                                        |
| Model 3: model 2 + tumor characteristics (i.e., tumor size and tumor grade) | 297,246 (43.35) | 3,722,497 (47.57) |                                        |
| Model 4 (full model): model 3 + cancer treatment (i.e., chemotherapy/radiotherapy and surgery) | 61,799 (9.01)     | 734,335 (9.38)    |                                        |
| Model 5: model 4 + cancer treatment type (i.e., chemotherapy/radiotherapy and surgery) | 170,021 (24.79) | 2,069,948 (26.45) |                                        |
| Model 6: model 5 + cancer treatment duration (i.e., chemotherapy/radiotherapy and surgery) | 155,702 (22.71) | 1,900,555 (24.29) |                                        |
| Model 7: model 6 + cancer treatment intensity (i.e., chemotherapy/radiotherapy and surgery) | 298,205 (43.49) | 3,119,871 (39.87) |                                        |

\(a\) Cox model was used to estimate hazard ratios (HRs), adjusted for covariates listed in the model information column.

Table 2: Risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by different adjustment strategies, compared with individuals with a first malignant neoplasm (FMN) diagnosis.

| Model information                           | SMN \(N=685727\) | FMN \(N=7824709\) | Hazard ratio (95% confidence interval) |
|---------------------------------------------|--------------------|--------------------|----------------------------------------|
| Different adjustment strategies\(a\)       |                    |                    |                                        |
| Model 1: adjusted for birth year, sex, and calendar year | 66,741 (9.73)     | 791,353 (10.11)    |                                        |
| Model 2: model 1 + sociodemographic factors (i.e., race, cohabitation status, insurance, and state) | 321,740 (46.92) | 3,310,859 (42.31) |                                        |
| Model 3: model 2 + tumor characteristics (i.e., tumor size and tumor grade) | 297,246 (43.35) | 3,722,497 (47.57) |                                        |
| Model 4 (full model): model 3 + cancer treatment (i.e., chemotherapy/radiotherapy and surgery) | 61,799 (9.01)     | 734,335 (9.38)    |                                        |
| Model 5: model 4 + cancer treatment type (i.e., chemotherapy/radiotherapy and surgery) | 170,021 (24.79) | 2,069,948 (26.45) |                                        |
| Model 6: model 5 + cancer treatment duration (i.e., chemotherapy/radiotherapy and surgery) | 155,702 (22.71) | 1,900,555 (24.29) |                                        |
| Model 7: model 6 + cancer treatment intensity (i.e., chemotherapy/radiotherapy and surgery) | 298,205 (43.49) | 3,119,871 (39.87) |                                        |

\(a\) Cox model was used to estimate hazard ratios (HRs), adjusted for covariates listed in the model information column.

Figure 2: Risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by sites of SMN or lifestyle-related cancers, compared with individuals with a first malignant neoplasm (FMN) diagnosis. \(a\) Cox model was used to estimate hazard ratios (HRs), adjusted for birth year, sex, calendar year, race, cohabitation status, insurance, state, tumor size, grade, chemotherapy/radiotherapy, and surgery. \(b\) Central nervous system. \(c\) Esophageal, liver, or pancreatic cancer.
Table 3: Risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by different characteristics, compared with individuals with a first malignant neoplasm (FMN) diagnosis.

|                          | No. of suicide cases/no. of accumulated person-years × 10,000 (incidence rate/10,000 person-years) | Hazard ratio$^a$ (95% confidence interval) | $P_{\text{difference}}$ |
|--------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------|
| **By age at diagnosis (by quantile), y** |                                                                                                  |                                           | 0.0003                   |
| <55                      | 75/315,337.92 (2.38)                                                                             | 2780/15,810,144.58 (1.76)                | 1.38 (1.09–1.73)         |
| 55–65                    | 223/687,006.17 (3.25)                                                                            | 3234/13,794,478.21 (2.34)               | 1.32 (1.15–1.52)         |
| 66–75                    | 339/747,527.17 (4.53)                                                                            | 2816/9,059,181.29 (3.11)                | 1.33 (1.19–1.50)         |
| >75                      | 300/651,281.67 (4.61)                                                                            | 2100/5,442,154.83 (3.86)                | 0.96 (0.85–1.09)         |
| **By calendar year, y**  |                                                                                                  |                                           | 0.15                     |
| 1975–1984                | 68/116,017.71 (5.86)                                                                             | 1584/5,375,711.83 (2.95)                | 1.43 (1.12–1.82)         |
| 1985–1994                | 191/364,410.29 (5.24)                                                                            | 2296/8,174,559.13 (2.81)               | 1.40 (1.21–1.63)         |
| 1995–2004                | 260/789,908.79 (3.29)                                                                            | 3473/16,284,736.13 (2.13)              | 1.21 (1.06–1.37)         |
| 2005–2016                | 418/1,130,816.13 (3.70)                                                                          | 3577/14,270,951.83 (2.51)              | 1.17 (1.05–1.29)         |
| **By sex**               |                                                                                                  |                                           | 0.99                     |
| Male                     | 825/1,320,654.54 (6.25)                                                                          | 9030/20,956,633.67 (4.31)              | 1.20 (1.11–1.29)         |
| Female                   | 112/1,080,498.38 (1.04)                                                                           | 1900/23,149,325.25 (0.82)              | 1.20 (0.99–1.46)         |
| **By race**              |                                                                                                  |                                           | 0.066                    |
| White                    | 880/2,091,732.79 (4.21)                                                                          | 10060/36,981,749.92 (2.72)             | 1.23 (1.15–1.32)         |
| Black                    | 38/181,568.13 (2.09)                                                                             | 368/3,798,398.25 (0.97)                | 1.70 (1.21–2.41)         |
| **By cohabitation status** |                                                                                                  |                                           | 0.45                     |
| Cohabitation             | 336/746,244.92 (4.50)                                                                            | 4120/13,911,216.5 (2.96)               | 1.20 (1.07–1.35)         |
| Noncohabitation          | 546/1,493,855.42 (3.65)                                                                          | 5939/27,156,872.79 (2.19)              | 1.27 (1.16–1.39)         |
| **By tumor size, cm**    |                                                                                                  |                                           | 0.057                    |
| <1.5                     | 79/321,027 (2.46)                                                                                | 758/5,869,076.38 (1.29)                | 1.39 (1.10–1.76)         |
| ≥1.5                     | 366/1,025,931.79 (3.57)                                                                          | 3640/16,163,041.38 (2.25)              | 1.08 (0.97–1.21)         |
| **By tumor grade**       |                                                                                                  |                                           | 0.81                     |
| Well differentiated      | 86/306,398.13 (2.81)                                                                             | 1000/5,384,767.58 (1.86)               | 1.29 (1.03–1.61)         |
| Moderately differentiated | 275/769,611.54 (3.57)                                                                            | 3179/14,044,744.63 (2.26)              | 1.37 (1.21–1.56)         |
| Poorly differentiated/ undifferentiated | 252/473,608.54 (5.32)                                                                            | 2696/8,978,857.25 (3.00)              | 1.40 (1.23–1.60)         |
| **By chemotherapy/radiotherapy** |                                                                                                  |                                           | 0.91                     |
| No/unknown               | 630/1,590,770.13 (3.96)                                                                          | 6701/25,942,336.79 (2.58)              | 1.22 (1.13–1.33)         |
| Yes                      | 307/810,382.79 (3.79)                                                                            | 4229/18,163,622.13 (2.33)              | 1.23 (1.09–1.38)         |
| **By surgery**           |                                                                                                  |                                           | 0.0011                   |
| No/unknown               | 397/662,482.42 (5.99)                                                                            | 4654/10,600,572.79 (4.39)              | 1.07 (0.96–1.18)         |
| Yes                      | 540/1,738,670.5 (3.11)                                                                           | 6276/33,505,386.13 (1.87)              | 1.35 (1.23–1.48)         |
| **By time interval between FMN and SMN, y** |                                                                                                  |                                           | 0.84                     |
| ≤1                       | 246/630,900.92 (3.90)                                                                            | 10930/44,105,958.92 (2.48)             | 1.24 (1.09–1.40)         |
| 2–3                      | 195/464,630.75 (4.20)                                                                            | 10930/44,105,958.92 (2.48)             | 1.29 (1.12–1.49)         |
| 4–6                      | 189/486,033.92 (3.89)                                                                            | 10930/44,105,958.92 (2.48)             | 1.19 (1.03–1.38)         |
radiotherapy, and the time interval between FMN and SMN (Table 3). Likewise, similar estimates were found across different follow-up periods ($P_{\text{difference}} = 0.95$; Table 3). However, the HRs were somewhat higher among younger patients ($P_{\text{difference}} = 0.0003$) and patients treated with surgery ($P_{\text{difference}} = 0.0011$). A greater risk of suicide was also observed in SMN patients who underwent chemotherapy/radiotherapy ($P_{\text{difference}} = 0.013$) and surgery ($P_{\text{difference}} = 0.045$) for their first malignancy (Table 4).

The calculation of SMRs, using the general US population as a reference, revealed a further increased risk of suicide among SMN patients (SMR 1.65 (95% CI 1.54–1.75)) relative to FMN patients (SMR 1.29 (95% CI 1.26–1.31); $P_{\text{difference}} < 0.0001$). Across different follow-up periods, the changing patterns were similar between SMN patients and FMN patients, both of which showed the highest estimates within the first 3 months after cancer diagnosis (Figure 3 and Supplementary Table 2). The excess risk then experienced a rapid decline but remained at a significant level for up to 5 years.

In sensitivity analysis, we observed largely comparable results after excluding SMN patients whose first malignancy was at the same tumor site (Supplementary Table 3). In addition, the calculation of the $E$-value revealed that a minimal magnitude of 1.76-fold increased risk of suicide death that was associated with the unmeasured confounders would be needed to entirely explain the observed association.

### 4. Discussion

To the best of our knowledge, this is the first large-scale cohort study that examined the risk of suicide among cancer survivors who developed a SMN, using population-based register data in the USA. We found that compared with FMN patients, patients with a SMN diagnosis, particularly those diagnosed at a younger age, with aggressive SMN, or had received surgery treatment for the SMN, were at an increased risk of suicide death within the entire follow-up period after adjusting for many potential confounders. Importantly, as the calculations of relative risk (i.e., SMR) of suicidal death relative to the general US population revealed a high-risk time period (i.e., the first 3 months after SMN diagnosis), such finding highlights the time window for suicide intervention among SMN patients.

The immediate suicide risk following a FMN diagnosis has been well estimated in previous studies, suggesting cancer diagnosis as an acute stressor that can lead to suicide behaviors [11, 13, 23]. Nevertheless, with regard to SMN, data from large longitudinal studies are scarce. We therefore have limited knowledge about the suicide risk among SMN patients, and whether the level of such a risk is comparable or superior to that among FMN patients. In our study, we, for the first time, showed a significant impact of a SMN diagnosis on the subsequent suicide risk, relative to a FMN diagnosis. Despite the absence of comparable data from studies with a similar design, our findings gain support from previous investigations that consistently suggested cancer survivors with multiple primary cancers had more frequent or greater psychological distress than survivors of single cancer, which was measured by the number of days of self-reported mental-health-related feelings in the past month [15–17]. Such results indicate that a diagnosis of subsequent primary cancer might bring additional adverse effects on the mental health among cancer survivors. Moreover, in a study also based on the SEER database, it focused on the sex disparity of suicide risk among cancer patients, and the authors reported an increased risk for suicidal death among secondary primary head and neck cancer patients, compared with those with head and neck cancer as the first primary cancer, which is in line with our present results [24]. Furthermore, the comparison with the general population corroborates the findings by illustrating consistently higher SMRs among SMN than FMN patients over time since the diagnosis. Those two groups of patients, however, shared a temporal pattern of suicide death risk, with the period shortly after the cancer diagnosis (i.e., within 3 months for both SMN and FMN) as a high-risk time period with the

| Follow-up Period | No. of suicide cases/no. of accumulated person-years × 10,000 (incidence rate/10,000 person-years) | Hazard ratioa (95% confidence interval) | $P_{\text{difference}}$ |
|------------------|---------------------------------------------------------------|----------------------------------------|------------------------|
| >6 years         | 307/819,587.33 (3.75)                                         | 1.20 (1.07–1.34)                       | 0.95                   |
| 1–2 years        | 376/509,112.92 (7.39)                                         | 1.18 (1.06–1.31)                       |                        |
| 3–4 years        | 153/784,901.33 (1.95)                                         | 1.26 (1.06–1.49)                       |                        |
| 5–10 years       | 199/1,328,072.67 (1.50)                                       | 1.22 (1.06–1.42)                       |                        |
| >10 years        | 143/1,387,784.33 (1.03)                                       | 1.24 (1.05–1.48)                       |                        |
|                  | 66/904,527.5 (0.73)                                           | 1.28 (1.00–1.63)                       |                        |

*Cox model was used to estimate hazard ratios (HRs), adjusted for birth year, sex, calendar year, race, cohabitation status, insurance, state, tumor size, grade, chemotherapy/radiotherapy, and surgery.*
most frequent suicide deaths. The observed temporal pattern was in accordance with our previous findings on the risk patterns of mental disorders after the cancer diagnosis [8]. These results further indicate the psychological stress induced by the diagnosis of the subsequent malignant neoplasm and call for attention to monitor the mental health status of cancer survivors, especially for those who experienced a recent diagnosis of cancer, and to carry out

### Table 4: Risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by characteristics of the first malignancy, compared with individuals with a first malignant neoplasm (FMN) diagnosis.

| By FMN tumor size, cm | No. of suicide cases/no. of accumulated person-years × 10,000 (incidence rate/10,000 person-years) | Hazard ratioa (95% confidence interval) | P_difference |
|----------------------|-------------------------------------------------------------------------------------------------|----------------------------------------|--------------|
| <1.5                 | SMN 62/260,141.08 (2.38) || FMN 758/5,869,076.38 (1.29) | 1.55 (0.77–3.12) | 0.57 |
| ≥1.5                 | SMN 285/839,718.17 (3.39) || FMN 3,640/16,163,041.38 (2.25) | 1.26 (1.06–1.50) | 0.54 |
| By FMN grade         | Well differentiated | SMN 118/318,247.38 (3.71) || FMN 1,000/5,384,767.58 (1.86) | 1.39 (0.82–2.36) | 0.013 |
|                      | Moderately differentiated | SMN 334/817,983.33 (4.08) || FMN 3,179/14,044,744.63 (2.26) | 1.65 (1.37–1.99) | 0.45 |
|                      | Poorly differentiated/ undifferentiated | SMN 212/466,502.54 (4.54) || FMN 2,696/8,978,857.25 (3.00) | 1.86 (1.47–2.37) | 0.045 |
| By FMN chemotherapy/radiotherapy | No/unknown | SMN 590/1,525,397.25 (3.87) || FMN 6,701/25,942,336.79 (2.58) | 1.28 (1.16–1.41) | 0.0013 |
|                      | Yes | SMN 347/875,755.67 (3.96) || FMN 4,229/18,163,622.13 (2.33) | 1.64 (1.39–1.95) | 0.045 |
| By FMN surgery        | No/unknown | SMN 272/512,397.08 (5.31) || FMN 4,654/10,600,572.79 (4.39) | 1.18 (0.99–1.40) | 0.74 |
|                      | Yes | SMN 665/1,888,755.83 (3.52) || FMN 6,276/33,505,386.13 (1.87) | 1.45 (1.31–1.61) | 0.045 |

aCox model was used to estimate hazard ratios (HRs), adjusted for birth year, sex, calendar year, race, cohabitation status, insurance, state, tumor size, grade, chemotherapy/radiotherapy, and surgery.

**Figure 3:** Change of the suicide standardized mortality ratios (SMRs) over follow-up periods among patients with first malignant neoplasm (FMN) or second malignant neoplasm (SMN), compared with the general population. The expected number for suicide deaths during the study period was derived from age (5 year groups), sex, and calendar year (1 year groups) suicide death rate for the USA.
necessary thought interventions, such as initiating timely psychosocial care [25] and providing prompt suicide risk screening [26].

Besides the repeated exposure to a notorious stressful event such as cancer diagnosis [27], other explanations for the phenomenon that SMN patients might suffer from a higher level of psychological stress, in comparison with FMN patients, include poorer mental health status (e.g., being more likely to have the serious psychological disorder) [15], worse overall health condition (e.g., being reported more health-related bed days) [15], poorer quality of life [28], and undermined socioeconomic status due to the treatment of SMN [29]. In addition, even if patients eventually survived their cancer, cancer treatment itself could be invasive and painful and often accompanied by severe side effects that could traumatize cancer survivors for an extended period of time [30]. Therefore, the fear of cancer treatment can be another underlying trigger that contributes to more suicidal behaviors among SMN patients. Indeed, in our analysis, we found SMN patients who underwent chemotherapy/radiotherapy or surgery for their FMN had a higher relative risk for suicide death, providing supportive evidence to this notion.

The major merits of our study include the large population-based sample of cancer survivors across the USA and the complete follow-up period, which ensures the representativeness of the study sample. Also, the large sample size enabled detailed analyses for all subgroups, especially by different follow-up times since diagnosis. The data on cancer diagnosis and cause of death are collected prospectively and independently, which minimizes the risk of information bias. In addition, using the enriched information on tumor characteristics and cancer treatment, we were able to control for important tumor- and treatment-related confounders in our analysis.

Our study has several limitations. First, the misclassification of some causes of death may be a concern. However, it is unlikely that the misclassification would differ substantially between patients with malignancy and the general population. Second, the SEER program merely recruited cancer patients, lacking a cancer-free group as a reference. However, the comparisons of the suicide rates between our study population and the age-, calendar-year-, and sex-matched general population through SMR calculation facilitate the identification of high-risk time window of suicide for timely and effective intervention. Third, due to the lack of information on some potential confounders, such as lifestyle factors, preexisting psychiatric disorders, and history of somatic illness, the residual confounding could be an issue. During analysis, we have made extra efforts by analyzing lifestyle-related cancers (i.e., alcohol- and smoking-related cancers) separately. As such analyses led to comparable estimates, it seems the lifestyle factor did not substantially modify the observed associations. The role of preexisting psychiatric disorders and history of somatic illness need to be assessed in further investigations. However, the calculated $E$-value suggested that the observed association was unlikely to be entirely explained by the unmeasured confounding. Finally, the generalization of our findings to the entire nation or other populations needs cautions since SEER areas had better case completeness, greater economic disadvantage, and greater minority diversity than non-SEER areas [31]. Despite these discrepancies, we assume these factors should have a limited effect on the studied association as we compared individuals with FMN to those with SMN in our study, all of which come from SEER areas.

In conclusion, this population-based cohort in the USA indicated that cancer survivors receiving a SMN diagnosis were at an increased risk of suicide, compared with either patients with FMN or the general population. The excess risk was most pronounced within the time period immediately after the SMN diagnosis, highlighting the necessity of providing timely psychological support to patients suffering SMN.

**Data Availability**

The data analyzed in this study were obtained from the Surveillance, Epidemiology, and End Results Program (https://seer.cancer.gov/).

**Ethical Approval**

This study was approved by the Biomedical Research Ethics Committee of West China Hospital (2020.393).

**Disclosure**

Part of this work was presented as an oral presentation at the World Congress of Epidemiology on 3–6 September 2021.

**Conflicts of Interest**

The authors declare that there are no potential conflicts of interest.

**Authors’ Contributions**

DL, HS, and HY were responsible for the study’s concept and design. YQ did the project management. HY, CW, and JW did the data cleaning and analysis. HY, DL, and HS interpreted the data. HY, DL, and HS drafted the manuscript. YS did the language edits. All the authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Acknowledgments**

The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-based database. This work was supported by the National Natural Science Foundation of China (grant no. 81971262 to HS), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (grant no. ZYYC21005 to HS), and
Supplementary Materials

Supplementary Table 1: International Classification of Disease Oncology (ICD-O) third version codes for diagnoses used in this study. Supplementary Table 2: change of the suicide standardized mortality ratios (SMRs) over follow-up periods among patients with first malignant neoplasm (FMN) or second malignant neoplasm (SMN), compared with the general population. Supplementary Table 3: sensitive analysis of the risk of suicide among individuals with a second malignant neoplasm (SMN) diagnosis, by excluding SMN patients with a prior history of first malignant neoplasm (FMN) at the same tumor site (N = 40,076), compared with individuals with FMN.

References

[1] K. D. Miller, L. Nogueira, A. B. Mariotto et al., “Cancer treatment and survivorship statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 5, pp. 363–385, 2019.

[2] J. Maddams, M. Utley, and H. Møller, “Projections of cancer prevalence in the United Kingdom, 2010-2040,” British Journal of Cancer, vol. 107, no. 7, pp. 1195–1202, 2012.

[3] C. Allemani, T. Matsuda, V. Di Carlo et al., “Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries,” Lancet (London, England), vol. 391, no. 10125, pp. 1023–1075, 2018.

[4] Y. Ye, P. Otahal, K. E. Wills, A. L. Neil, and A. J. Venn, “Temporal trends in the risk of second primary cancers among survivors of adult-onset cancers, 1980 through 2013: an Australian population-based study,” Cancer, vol. 124, no. 8, pp. 1808–1818, 2018.

[5] L. B. Travis, S. D. Fossá, S. J. Schonfeld et al., “Second cancers among 40 576 testicular cancer patients: focus on long-term survivors,” JNCI: Journal of the National Cancer Institute, vol. 97, no. 18, pp. 1354–1365, 2005.

[6] N. Donin, C. Filson, A. Drakaki et al., “Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008,” Cancer, vol. 122, no. 19, pp. 3075–3086, 2016.

[7] A. Pitman, S. Suleman, N. Hyde, and A. Hodgkinson, “Depression and anxiety in patients with cancer,” BMJ (Clinical Research ed), vol. 361, p. 361, 2018.

[8] D. Lu, T. M. L. Andersson, K. Fall et al., “Clinical diagnosis of mental disorders immediately before and after cancer diagnosis,” JAMA Oncology, vol. 2, no. 9, pp. 1188–1196, 2016.

[9] K. Brasso, S. Ladelund, B. L. Frederiksen, and T. Jørgensen, “Psychological distress following fecal occult blood test in colorectal cancer screening - a population-based study,” Scandinavian Journal of Gastroenterology, vol. 45, no. 10, pp. 1211–1216, 2010.

[10] N. G. Zaorsky, Y. Zhang, L. Tuanquin, S. M. Bluethmann, H. S. Park, and V. M. Chinchilli, “Suicide among cancer patients,” Nature Communications, vol. 10, no. 1, p. 207, 2019.

[11] F. Fang, K. Fall, M. A. Mittelmen et al., “Suicide and cardiovascular death after a cancer diagnosis,” New England Journal of Medicine, vol. 366, no. 14, pp. 1310–1318, 2012.

[12] A. M. Saad, M. M. Gad, M. J. Al-Husseini et al., “Suicidal death within a year of a cancer diagnosis: a population-based study,” Cancer, vol. 125, no. 6, pp. 972–979, 2019.

[13] D. Lu, K. Fall, P. Sparén et al., “Suicide and suicide attempt after a cancer diagnosis among young individuals,” Annals of Oncology, vol. 24, no. 12, pp. 3112–3117, 2013.

[14] L. M. Sun, C. L. Lin, W. C. Shen, and C. H. Kao, “Suicide attempts in patients with head and neck cancer in Taiwan,” Psycho-Oncology, vol. 29, no. 6, pp. 1026–1035, 2020.

[15] M. A. Andrykowski, “Physical and mental health status of survivors of multiple cancer diagnoses,” Cancer, vol. 118, no. 14, pp. 3645–3653, 2012.

[16] J. L. Burris and M. A. Andrykowski, “Physical and mental health status and health behaviors of survivors of multiple cancers: a national, population-based study,” Annals of Behavioral Medicine, vol. 42, no. 3, pp. 304–312, 2011.

[17] M. A. Andrykowski and M. M. Goedendorp, “Distress and mental health care and medication use among survivors of multiple primary cancer diagnoses: findings from the 2016 national health interview survey,” Journal of Psychosomatic Research, vol. 134, Article ID 110137, 2020.

[18] D. Lu, L. B. Kenney, L. M. Vrooman, and C. J. Recklitis, “Long-term psychosocial well-being and quality of life among childhood cancer survivors who developed a subsequent malignant neoplasm,” Journal of Adolescent and Young Adult Oncology, vol. 10, no. 2, pp. 240–245, 2021.

[19] N. N. A. Howlader, M. Krapcho, D. Miller et al., Eds., SEER Cancer Statistics Review. 1975–2016, 2021, https://seer.cancer.gov/csr/1975_2016/.

[20] M. A. Duggan, W. F. Anderson, S. Altekruse, L. Penberthy, and M. E. Sherman, “The surveillance, epidemiology, and end results (SEER) program and pathology,” American Journal of Surgical Pathology, vol. 40, no. 12, pp. e94–e102, 2016.

[21] Q. Shen, D. Lu, M. E. Schelin et al., “Injuries before and after diagnosis of cancer: nationwide register based study,” BMJ (Clinical Research ed), vol. 354, p. 354, 2016.

[22] T. J. VanderWeede and P. Ding, “Sensitivity analysis in observational research: introducing the E-value,” Annals of Internal Medicine, vol. 167, no. 4, pp. 268–274, 2017.

[23] K. Fall, F. Fang, L. A. Mucci et al., “Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study,” PLoS Medicine, vol. 6, no. 12, Article ID e1000197, 2009.

[24] W. S. Kendal, “Suicide and cancer: a gender-comparative study,” Annals of Oncology, vol. 18, no. 2, pp. 381–387, 2007.

[25] G. Zalsman, K. Hawton, D. Wasserman et al., “Suicide prevention strategies revisited: 10 year systematic review,” The Lancet Psychiatry, vol. 3, no. 7, pp. 646–659, 2016.

[26] B. Gascon, Y. Leung, O. Espin-Garcia, G. Rodin, D. Chu, and M. Li, “Suicide Risk screening and suicide prevention in patients with cancer,” JNCI Cancer Spectrum, vol. 5, no. 4, Article ID pka057, 2021.

[27] R. S. Mia, “Psychological distress, health behaviors, and benefit finding in survivors of multiple primary cancers: results from the 2010 livestrong survey,” Oncology Nursing Society, vol. 44, pp. 703–711, 2017.

[28] C. C. Gotay, S. Ransom, and I. S. Pagano, “Quality of life in survivors of multiple primary cancers compared with cancer survivor controls,” Cancer, vol. 110, no. 9, pp. 2101–2109, 2007.

[29] S. M. Belcher, H. S. Donovan, D. H. Bovbjerg, P. R. Sherwood, G. B. Campbell, and S. M. Sereika, “Psychosocial risk factors for financial hardship and poor functional outcomes in
survivors of multiple primary cancers,” *Psycho-Oncology*, vol. 29, no. 3, pp. 507–516, 2020.

[30] A. L. Stanton, J. H. Rowland, and P. A. Ganz, “Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research,” *American Psychologist*, vol. 70, no. 2, pp. 159–174, 2015.

[31] T.-M. Kuo and L. R. Mobley, “How generalizable are the SEER registries to the cancer populations of the USA?” *Cancer Causes & Control*, vol. 27, no. 9, pp. 1117–1126, 2016.